Where to Get CJC-1295 + Ipamorelin in the UAE: A Patient Guide

The CJC-1295 and Ipamorelin blend is a staple of growth-hormone work, and its popularity has bred a familiar problem: plenty of sellers will list a two-peptide vial without ever proving what is inside it. A blend is harder to verify than a single compound, because now two peptides have to be correct, and a shortfall in either one is easy to hide.

This guide covers what each peptide is, why the two are used together, why the "No-DAC" distinction is not a technicality, how to read a blend Certificate of Analysis, and what is assessed before any of it applies to you.

These are two different tools acting on two different pathways, which is the whole reason they end up in the same vial. CJC-1295 (No-DAC), also known as Modified GRF 1-29, is a growth-hormone-releasing hormone (GHRH) analogue. It works on the GHRH receptor, the same receptor the body's own GHRH targets to signal a release of growth hormone. Ipamorelin is a different animal: a selective growth-hormone secretagogue acting as a ghrelin-receptor agonist, the class usually shortened to GHRP. One nudges the GHRH pathway, the other nudges the ghrelin pathway.

The "No-DAC" part matters and is worth getting right. DAC stands for Drug Affinity Complex, a modification that binds the peptide to albumin in the blood and drags its half-life out to days. No-DAC has no such complex, so it clears far faster and produces a shorter, pulsatile signal rather than a sustained one. That pulsatile profile is usually the point, because the body's own growth-hormone release is pulsatile. Ipamorelin, for its part, is noted for being relatively selective, with less effect on cortisol and prolactin than the older GHRPs it followed.

Because the two peptides act on separate receptors, they are combined for a pulsatile pattern of growth-hormone release that neither reliably produces alone. A GHRH analogue and a GHRP pull on different levers of the same system, and the interest lies in what happens when both move at once. The No-DAC version is the one usually chosen for this pairing, since its short profile lines up with the burst-style signalling the combination is aimed at. Put a sustained-release DAC version in the same vial and you have a different thing entirely, which is one reason it matters that someone competent knows which version is in front of you.

Nudging growth-hormone release is not a cosmetic intervention. The GH axis is tied to glucose handling and to IGF-1, and raising IGF-1 is specifically contraindicated in some conditions. There are also people for whom poor sleep, low energy or stalled recovery, the things that send people looking at this blend, have a different and more treatable cause entirely, from thyroid function to sleep apnoea to simple iron deficiency.

None of that is screenable from a product page. It needs a history, bloods, and someone who can read them. That is the actual argument against sourcing this yourself: not that the compounds are exotic, but that the decision to touch this axis at all should follow a proper look at what is going on, and where a diagnosis is the missing piece, that is your own doctor's job, not a supplier's.

Two questions decide whether a blend is usable. Is it pure, and is it actually both peptides in the ratio the label claims? Separate questions, separate tests, and a blend makes both harder.

Purity comes from high performance liquid chromatography (HPLC), which separates everything in the sample and reports each fraction as a percentage. On a blend, a good HPLC trace shows two clean peaks, one for CJC-1295, one for Ipamorelin, not a single smear. Identity comes from mass spectrometry (MS), which weighs each molecule and confirms both match their expected masses. The critical point: the CoA has to account for both peptides separately. A single purity number with no breakdown tells you nothing about whether one of the two is underdosed or missing.

A Certificate of Analysis (CoA) is the lab report for one production batch, and a blend needs an extra look:

• A batch or lot number that matches the vial in front of you. A generic CoA for "CJC-1295 / Ipamorelin" in the abstract is not a CoA for your material.
• Both peptides named on the report. If the document mentions only one of the two, it is not a CoA for a blend, whatever the listing says.
• An HPLC purity figure stated as a percentage rather than a vague "high purity" line. Anything under about 98 percent is worth a second look.
• Mass spectrometry results confirming the molecular weight of each peptide. On a blend this has to be done twice.
• A test date and the testing lab's name. A recent date and an independent lab mean someone with no stake in the outcome did the work.

The name that comes up most in this space is Janoshik Analytical, a European lab used widely because its reports can be checked through its own portal. Your consultant can show you the Janoshik report for the specific batch in your program.

The blend is supplied lyophilised, freeze-dried into a small pellet or film, which is the most stable state it has. Unopened vials belong at 2 to 8 degrees Celsius and out of the light. Once reconstituted, refrigerated and used within a few weeks. In UAE heat, a vial that spends two days in a warm van is how good documentation turns into nothing much at all, and there is no way to tell from the outside.

• No Certificate of Analysis, or vague "lab tested" wording with nothing you can actually read.
• A CoA covering only one of the two peptides, or a single blended purity figure with no per-peptide breakdown.
• No indication of whether the CJC-1295 is DAC or No-DAC. These behave differently and a seller who does not distinguish them may not know.
• Dosing instructions for humans from a seller with no clinician involved.
• A price dramatically below everyone else with no explanation for it.
• A seller you cannot actually reach, with no traceable business details.

Baseline is a consultation-led service, not a shop. You do not buy this blend here and we do not ship it to you on request.

You complete a short assessment, your consultant reads your history and your medications, and you have a consultation. Because this sits on the growth-hormone axis, that review covers glucose handling, IGF-1 and the contraindications that come with raising it, and it starts by asking whether something more ordinary explains what you came in with. If therapy is appropriate it is set out, dosed and monitored with follow-up bloods.

Every batch carries independent Janoshik documentation, and your consultant will show you the report for the batch you are given. You can see who you will be speaking to before you book. The consultation is AED 350, credited against your program if you go ahead.

This article is educational and is not a diagnosis, a treatment plan, or a recommendation to use any specific compound. A consultation decides what is appropriate for you.